Status:
TERMINATED
Study of Treatment Used for Migraine Headaches (MK-0974-076)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Brief Summary
This study will describe the reasons for triptan utilization patterns (continuation and discontinuation) in triptan-naïve participants and assess the stability of treatment utilization patterns over t...
Detailed Description
After study start, the Protocol was amended to clarifiy that the first triptan prescription must have been received by the participant within a time window of 3 months (± 2 weeks) prior to the partici...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- At least 18 years of age in the United States at the time of consent
- Physician-diagnosed migraine with or without aura
- At least two and up to a maximum of 8 moderate to severe migraine attacks during the 30 days prior to screening
- Initial triptan prescription 3 months (± 2 weeks) prior to being identified as eligible for this study, and triptan-naïve before that initial prescription
- Used triptan medication at least once within 6 months prior to the date of informed consent for screening
- Internet access and able to complete online surveys via electronic data entry
- Exclusion criteria:
- Treated with triptans prior to this study
- In active litigation and compensation issues including disability dispute cases with a Government agency
- Participation in a clinical trial within the last 90 days
Exclusion
Key Trial Info
Start Date :
May 19 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 23 2012
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT01421277
Start Date
May 19 2011
End Date
March 23 2012
Last Update
June 20 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.